DEA Reviews New Importer for Controlled Meds
Published Date: 2/13/2026
Notice
Summary
S&B Pharma LLC, also known as Norac Pharma, wants to become an official importer of certain controlled drugs. This means they’ll be allowed to bring in specific medicines that need special handling. If anyone has concerns or wants a hearing, they must speak up by March 16, 2026, so don’t miss the deadline!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Application to Import Two Schedule II Drugs
On January 13, 2026, S&B Pharma LLC DBA Norac Pharma applied to be registered to import ANPP (controlled substance code 8333, Schedule II) and Tapentadol (code 9780, Schedule II). The company plans to import intermediate forms of Tapentadol for further manufacturing and to import ANPP to bulk manufacture other controlled substances for distribution to its customers.
Finished Dosage Forms Not Authorized
The DEA notice states that authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale under this registration. The registration, if approved, is limited to the activities described in the application.
Deadline to Comment or Request Hearing
Registered bulk manufacturers of the affected drug classes and other applicants may submit comments or objections, or file a written request for a hearing, on or before March 16, 2026. Comments must be submitted electronically at https://www.regulations.gov and hearing requests must be sent to the DEA addresses listed in the notice.
Approval Conditional on Statutory Consistency
The notice states that approval of permit applications will occur only when the registrant's business activity is consistent with 21 U.S.C. 952(a)(2). That statutory consistency is a condition for authorization.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2026-02913 — Notice of OFAC Sanctions Action
The U.S. Treasury’s OFAC just blocked a Lebanese company called JOOD SARL and some related vessels because they support Hizballah. This means all their U.S.-related money and property are frozen, and Americans can’t do business with them. The action took effect on February 10, 2026, signaling serious financial consequences for those involved.
Next: 2026-02917 — State of Wyoming: NRC Staff Assessment of a Proposed Amendment to the Agreement Between the Nuclear Regulatory Commission and the State of Wyoming
The Nuclear Regulatory Commission (NRC) is proposing changes to its agreement with Wyoming about how the state handles certain nuclear materials. This update affects Wyoming’s safety rules and staffing for managing these materials, aiming to keep everyone safe and sound. The public can share their thoughts by March 2, 2026, before any final decisions are made.